Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac

Patamatamkul, Samadhi; Buranrat, Benjaporn; Thammawat, Sutthiwan

doi:10.1101/2021.09.25.21264099

Cited by 5 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A heterologous BNT162b2 booster (third) dose after the 2-dose CoronaVac primary series enhanced humoral and cellular responses. 25 , 28 , 42 , 43 Broad neutralization of SARS-CoV-2 variants was higher with a heterologous BNT162b2 booster (third) dose after a 2-dose CoronaVac primary series compared with a homologous CoronaVac booster, 29 including against Delta 34 and Omicron 11 variants. Similar results were observed among studies that pooled data from patients receiving either of the two authorized mRNA vaccines (BNT162b2 and mRNA-1273) as a booster after primary vaccination with an inactivated vaccine.…”

Section: Results Of Evidence Synthesismentioning

confidence: 98%

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

Kyaw

Spinardi²,

Zhang

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable programmatic resilience and can catalyze vaccine confidence and coverage. Inactivated SARS-CoV-2 vaccines are among the most widely used vaccines worldwide. This review synthesizes the available evidence identified as of May 26, 2022, on the safety, immunogenicity, and effectiveness of a heterologous BNT162b2 (Pfizer-BioNTech) mRNA vaccine booster dose after an inactivated SARS-CoV-2 vaccine primary series, to help protect against COVID-19. Evidence showed that the heterologous BNT16b2 mRNA vaccine booster enhances immunogenicity and improves vaccine effectiveness against COVID-19, and no new safety concerns were identified with heterologous inactivated primary series with mRNA booster combinations.

show abstract

Section: Results Of Evidence Synthesismentioning

confidence: 98%

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

Kyaw

Spinardi²,

Zhang

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…In addition to this, the advent of highly transmissive mutants has instigated talks on booster doses and booster policies targeting groups with high-risk occupational exposure, compromised immunity and advanced age (Krause et al, 2021;Parums, 2021). Since July 2021, some countries had begun administering boosters including heterologous booster shots which resulted in elevated antibody titers as well as reduced infection rates and severe illnesses by a factor of 11.3 and 19.5 respectively (Bar-On et al, 2021;Bensouna et al, 2021;Patamatamkul et al, 2021). However, most studies largely involved non-pregnant, older, or medically ill adults, thus may not be applicable to the general population.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 seroprevalence and antibody trends in vaccinated, multi-ethnic healthcare employees

C.C.¹

2021

Trop Biomed

View full text Add to dashboard Cite

Understanding of antibody kinetics against SARS-CoV-2 and its vaccines is rapidly evolving. This study aims to (1) determine post-vaccination seroprevalence; (2) compare antibody levels between vaccine types and various clinical/demographic determinants; and (3) determine post-vaccination antibody concentrations against time. This is a retrospective cross-sectional study involving 148 healthcare employees all over Malaysia. IgG Spike (RBD), IgM Spike and IgG Nucleocapsid concentration medians were compared using Mann-Whitney U or Kruskal-Wallis tests. Chi Square and Spearman correlation coefficient tests were performed to identify variables associated with antibody titers. A scatter plot of IgG Spike (RBD) against time from last vaccine dose was also plotted. At 1-month post-vaccination, all employees successfully seroconverted regardless of vaccine type, health status and COVID-19 history. Comirnaty, convalescent, female or Malay vaccinees had significantly higher IgG Spike (RBD) titers compared to their respective counterparts. No correlation was found between age and IgG Spike (RBD) levels. Concentration of all three antibodies waned with time post-vaccination, with IgM Spike and IgG Nucleocapsid waning faster than IgG Spike (RBD).

show abstract

Efficacy and safety of COVID-19 vaccines

Graña

Ghosn

Evrenoglou

et al. 2022

Cochrane Database of Systematic Reviews

181

135

View full text Add to dashboard Cite

Background Different forms of vaccines have been developed to prevent the SARS‐CoV‐2 virus and subsequent COVID‐19 disease. Several are in widespread use globally. Objectives To assess the efficacy and safety of COVID‐19 vaccines (as a full primary vaccination series or a booster dose) against SARS‐CoV‐2. Search methods We searched the Cochrane COVID‐19 Study Register and the COVID‐19 L·OVE platform (last search date 5 November 2021). We also searched the WHO International Clinical Trials Registry Platform, regulatory agency websites, and Retraction Watch. Selection criteria We included randomized controlled trials (RCTs) comparing COVID‐19 vaccines to placebo, no vaccine, other active vaccines, or other vaccine schedules. Data collection and analysis We used standard Cochrane methods. We used GRADE to assess the certainty of evidence for all except immunogenicity outcomes. We synthesized data for each vaccine separately and presented summary effect estimates with 95% confidence intervals (CIs). Main results We included and analyzed 41 RCTs assessing 12 different vaccines, including homologous and heterologous vaccine schedules and the effect of booster doses. Thirty‐two RCTs were multicentre and five were multinational. The sample sizes of RCTs were 60 to 44,325 participants. Participants were aged: 18 years or older in 36 RCTs; 12 years or older in one RCT; 12 to 17 years in two RCTs; and three to 17 years in two RCTs. Twenty‐nine RCTs provided results for individuals aged over 60 years, and three RCTs included immunocompromized patients. No trials included pregnant women. Sixteen RCTs had two‐month follow‐up or less, 20 RCTs had two to six months, and five RCTs had greater than six to 12 months or less. Eighteen reports were based on preplanned interim analyses. Overall risk of bias was low for all outcomes in eight RCTs, while 33 had concerns for at least one outcome. We identified 343 registered RCTs with results not yet available. This abstract reports results for the critical outcomes of confirmed symptomatic COVID‐19, severe and critical COVID‐19, and serious adverse events only for the 10 WHO‐approved vaccines. For remaining outcomes and vaccines, see main text. The evidence for mortality was generally sparse and of low or very low certainty for all WHO‐approved vaccines, except AD26.COV2.S (Janssen), which probably reduces the risk of all‐cause mortality (risk ratio (RR) 0.25, 95% CI 0.09 to 0.67; 1 RCT, 43,783 participants; high‐certainty evidence). Confirmed symptomatic COVID‐19 High‐certainty evidence found that BNT162b2 (BioNtech/Fosun Pharma/Pfizer), mRNA‐1273 (ModernaTx), ChAdOx1 (Oxford/AstraZeneca), Ad26.COV2.S, BBIBP‐CorV (Sinopharm‐Beijing), and BBV152 (Bharat Biotect) reduce the incidence of symptomatic COVI...

show abstract

Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac

Cited by 5 publications

References 5 publications

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

SARS-CoV-2 seroprevalence and antibody trends in vaccinated, multi-ethnic healthcare employees

Efficacy and safety of COVID-19 vaccines

Contact Info

Product

Resources

About